Kura Oncology, Inc. (KURA)
NASDAQ
Closed
Oct 23, 2026
Day's Range
9.2852 wk Range
7.36Overview - KURA - Kura Oncology, Inc.
Key Statistics
Valuation
Enterprise Value
313.19M
P/E (Trailing)
-2.85
P/E (Forward)
-3.86
PEG Ratio
-1.07
Price / Sales (TTM)
10.45
Price / Book
16.69
EV / EBITDA
-0.98
Profitability
Gross Margin
98.83%
Profit Margin
99.91%
Operating Margin
-349.76%
Return on Assets
-31.30%
Return on Equity
-167.70%
Ownership
Shares Outstanding
88.95M
Float
70.52M
Short % of Shares Outstanding
16.64%
Held by Insiders
1.39%
Held by Institutions
100.21%
Price stats
Beta
0.46
50-Day Avg
11.32
200-Day Avg
9.79
Analyst Consensus
16 analysts
Average price target
$ 31.85Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - KURA - Kura Oncology, Inc.
Peers - KURA - Kura Oncology, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- KURANASDAQKura Oncology, Inc.807.76MMarket Cap-10.02%52-week change-2.86P/E (Trailing)99.91%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - KURA - Kura Oncology, Inc.
About
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
